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Abstract
Several high-profile outbreaks have drawn attention to invasive fungal infections (IFIs) as an 
increasingly important public health problem. IFI outbreaks are caused by many different fungal 
pathogens and are associated with numerous settings and sources. In the community, IFI outbreaks 
often occur among people without predisposing medical conditions and are frequently precipitated 
by environmental disruption. Health-care-associated IFI outbreaks have been linked to suboptimal 
hospital environmental conditions, transmission via health-care workers’ hands, contaminated 
medical products, and transplantation of infected organs. Outbreak investigations provide 
important insights into the epidemiology of IFIs, uncover risk factors for infection, and identify 
opportunities for preventing similar events in the future. Well recognised challenges with IFI 
outbreak recognition, response, and prevention include the need for improved rapid diagnostic 
methods, the absence of routine surveillance for most IFIs, adherence to infection control 
practices, and health-care provider awareness. Additionally, IFI outbreak investigations have 
revealed several emerging issues, including new populations at risk because of travel or relocation, 
occupation, or immunosuppression; fungal pathogens appearing in geographical areas in which 
they have not been previously recognised; and contaminated compounded medications. This report 
highlights notable IFI outbreaks in the past decade, with an emphasis on these emerging 
challenges in the USA.
Introduction
Invasive fungal infections (IFIs) have received increased attention as an emerging public 
health problem in the past decade, in part because of several high-profile outbreaks.1 IFIs are 
often difficult to detect and treat, and can be associated with substantial morbidity and 
mortality.2 These issues are becoming increasingly apparent as many IFIs appear to be on 
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the rise globally.3,4 The observed increases in IFIs are multifaceted and include host factors, 
such as a larger at risk immunosuppressed population, or travel or relocation of immune-
naive people to areas in which particular IFIs are geographically restricted; pathogen factors, 
such as new virulence or resistance mechanisms and expansion to new endemic areas; and 
environmental factors, including changing land use patterns, agricultural antifungal use, and 
climate change.3 Outbreak investigations can provide important insights into the 
epidemiology and sources of IFIs, including changes in the aforementioned host, pathogen, 
and environmental factors.
IFI outbreaks usually result from exposure to a common environmental source or a 
contaminated medical product. Investigations of IFI outbreaks are often challenging but are 
essential to identify the source and stop the outbreak. Furthermore, outbreak investigations 
often yield new and important descriptive epidemiological information, uncover risk factors 
for infection, help identify gaps in awareness and infection control, and identify 
opportunities for prevention of similar events in the future. This report highlights notable IFI 
outbreaks and describes new and existing challenges that arise during outbreak 
investigations. Numerous other outbreaks not described in detail illustrate the diversity of 
fungal pathogens and their ecological niches (table).
Community-acquired fungal disease outbreaks
Fungi are abundant in and essential to the natural environment, and only a tiny fraction of all 
fungi are pathogenic. Fungi have long been known as pathogens of crops and have caused 
widespread population declines in bats and amphibians, linked to both global movement of 
people and goods and environmental modification.18 Fungi pathogenic to human beings 
exist in many different natural habitats, but the burden of IFIs is generally observed to be 
highest in tropical and subtropical climates, where fungi capable of growing at human body 
temperatures can thrive.19 The emergence of Cryptococcus gattii, formerly restricted to 
tropical and subtropical climates, in a temperate region of North America, provides evidence 
that fungal pathogens can spread to new geographical areas. Other pathogenic fungi, such as 
histoplasma, coccidioides, and blastomyces, have existed within specific ecological niches 
and have been broadly restricted to particular regions of the world. However, climate and 
other environmental changes could also be altering the distribution of these fungi. IFI 
outbreaks in the community often occur among people without predisposing medical 
conditions and are frequently precipitated by environmental disruption, either on a small 
scale in relation to excavation, construction, or similar activities, or on a larger scale (eg, 
related to natural disasters).20
C gattii was believed to be restricted to tropical and subtropical regions, particularly 
Australia, Papua New Guinea, and South America. In the 1990s, it emerged in the temperate 
climate of British Columbia, Canada,21 eventually moving south into the USA Pacific 
Northwest (PNW), where nearly 100 cases were reported during 2004–11.22 C gattii’s 
molecular epidemiology has been well studied; most cases related to the PNW epidemic 
were caused by molecular type VGII, which contrasts with molecular type VGIII, seen in 
southern California and elsewhere in the USA. Phylogenetic analyses indicate that the VGII 
type likely originated in South America and underwent multiple dispersal events, but exactly 
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how and why C gattii arrived in the PNW remains unknown.23–25 As a result of this 
outbreak, Oregon and Washington began requiring physicians and laboratories to report C 
gattii cases to public health authorities, and laboratories began to differentiate C gattii from 
Cryptococcus neoformans.
Histoplasmosis is generally believed to be the most common endemic mycosis worldwide, 
although the exact number of new infections annually is unknown. Histoplasma spp grow 
particularly well in soil contaminated with bird or bat droppings, and histoplasmosis 
outbreaks are often associated with point-source exposures or disturbance of contaminated 
soil.26 Outbreaks occur regularly in the USA, with 105 outbreaks reported during 1938–
2013, although many more outbreaks are not recognised, investigated, or published.26 More 
than 40% of the published histoplasmosis outbreaks in the USA involved workers in an 
occupational setting, and birds, bats, or their droppings were implicated in 86% of 
workplace-related outbreaks.26 The US Centers for Disease Control and Prevention National 
Institute for Occupational Safety and Health (CDC-NIOSH) has issued guidance for 
histoplasmosis prevention among workers, as occupational health continues to be an 
important issue in histoplasmosis outbreaks.27
In Central and South America, numerous histoplasmosis outbreaks have been described 
among people who visited bat-infested caves.28 In 2015, an unusually severe outbreak 
occurred in the Dominican Republic, where histoplasmosis outbreaks had not been 
previously documented. In July, 2015, a group of 35 men cleared several tons of bat guano 
from tunnels that provided access for inspection and maintenance of a hydroelectric dam. 30 
men developed histoplasmosis, of whom 28 were hospitalised and three died, a case-fatality 
rate approximately ten times higher than is typically described in the USA; the high 
hospitalisation and mortality rates were probably related to a large inoculum within an 
enclosed space.29 Adequate respiratory protection was not used. Low awareness about 
histoplasmosis risk in this area contributed to the absence of adequate workplace 
precautions. CDC-NIOSH guidance regarding powered air purifying respirators and other 
expensive protective equipment would have been difficult to implement in this resource-
limited setting.27 Furthermore, diagnosis of histoplasmosis among ill workers was delayed 
because of the absence of in-country diagnostic capacity, and involved clinicians were 
unfamiliar with the treatment and management of histoplasmosis because it had never been 
previously diagnosed in the Dominican Republic. This outbreak underscores the need for 
improved diagnostic capacity for histoplasmosis throughout the Americas and the 
Caribbean.
Although nearly all reported histoplasmosis outbreaks have been associated with 
environmental disruption, such as disturbance of bird or bat droppings (reported in 40% of 
outbreaks), soil or plant matter disruption (32%), or demolition or construction (25%), many 
outbreaks show the possibility for cases to occur in people exposed to aerosolised spores, 
who were not directly involved in the outbreak-initiating activities.26 For example, an 
outbreak of 78 cases among prison inmates in central Illinois was associated with the 
removal of two trees where many birds had roosted.30 None of the inmates who participated 
in the tree removal developed acute histoplasmosis, which might reflect immunity to 
Histoplasma spp acquired during recurrent occupational soil exposures at the prison.30 
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Furthermore, inmates without evidence of histoplasmosis had a significantly longer median 
incarceration time than had the patients with histoplasma infection; most inmates previously 
resided in areas of Illinois where histoplasmosis is not frequently reported, suggesting that 
reduced immunity to Histoplasma spp could have had a role in this outbreak.30
Coccidioidomycosis is endemic to southwestern USA and large parts of Latin America. 
However, coccidioides has also been discovered north of its traditional geographical range, 
in southcentral Washington.31 Coccidioides’ environmental growth and distribution depends 
on temperature, precipitation, and other climate factors (and also might be associated with a 
rodent host); therefore, sporadic coccidioidomycosis cases and outbreaks are likely to be at 
least partly driven by climate conditions, rodent habitat, and environmental disruption 
events.32 Examples of past events leading to coccidioidomycosis outbreaks include an 
earthquake,33 a severe dust storm,34 archaeological excavation,35 and construction.36 
Similarly, during 2011–14, a large outbreak of 44 coccidioidomycosis cases occurred among 
workers who were constructing two solar power farms in San Luis Obispo County (CA, 
USA).37 Interviews with the affected workers (many of whom came from non-endemic areas 
and might have lacked immunity to coccidioides) revealed that 58% reported frequently 
performing soil disruption activities, but of those, only a quarter frequently used respiratory 
protection.37 Recommendations to prevent additional cases included improving dust control 
methods at construction sites and provision of appropriate respiratory protection; however, 
evidence is limited regarding whether these methods reduce coccidioidomycosis risk.37 
Similar prevention methods have also been attempted in other settings, including prisons in 
highly endemic areas of California. Despite use of these methods and exclusion of inmates 
at highest risk for coccidioidomycosis complications from eight prisons in California’s 
Central Valley beginning in 2006,38 coccidioidomycosis rates remained high in subsequent 
years. In 2011, rates at two prisons were two orders of magnitude higher than were rates in 
the surrounding counties in which the prisons were located, probably partly because most 
inmates in these two prisons resided in geographical are as with lower risk for 
coccidioidomycosis before incarceration.39 In January, 2015, a skin test to detect delayed-
type hypersensitivity to coccidioides, an indicator of past infection, was administered to 
nearly 40 000 inmates throughout California. Inmates with a negative skin test result have 
since been restricted from being housed in the two prisons with the highest 
coccidioidomycosis rates.40
Blastomycosis is much less common than histoplasmosis and coccidioidomycosis, with 
approximately 15 outbreaks in the USA reported in published literature since the 1950s.41 
Typical features of blastomycosis outbreaks include shared outdoor activities such as 
camping, hunting, or fishing, or exposure to construction or excavation, often near 
waterways. By contrast, patients in a large outbreak in Wisconsin during 2009–10 were not 
more likely than were controls to have these types of exposures.42 Instead, the outbreak was 
characterised by a high proportion of cases in Hmong people and unique case clustering 
within households and neighbourhoods, suggesting that multiple environmental foci were 
the likely cause.42
Community-acquired IFI outbreaks caused by moulds are uncommon because moulds 
typically affect immunosuppressed people. A noteworthy exception was an outbreak of 13 
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cases of soft-tissue mucormycosis caused by Apophysomyces trapeziformis in people who 
were severely injured during a tornado in Joplin (MO, USA) in 2011 (figure 1).43 Whole-
genome sequence typing (WGST) of isolates from patient wounds revealed four distinct but 
closely related strains of A trapeziformis, suggesting that the cases were related to one or 
more environmental sources rather than a health-care-associated source.43,44 Other examples 
of mould infections and outbreaks after natural disasters have been reviewed elsewhere.45 
Although these events are rare, they can result in substantial morbidity and mortality, 
therefore health-care providers should be aware of the possibility for IFIs after natural 
disasters. Broader disaster preparedness and response strategies related to health-care 
services could facilitate faster diagnosis for disaster-associated IFIs and administration of 
appropriate treatment.45
Health-care-associated outbreaks
Aspergillus, mucormycetes, and other moulds are ubiquitous in the outdoor and indoor 
environment. Numerous hospital-associated outbreaks of aspergillosis and mucormycosis 
have occurred; hospital construction, indoor water damage, and improper air filtration have 
all been associated with these outbreaks. Less commonly, IFI outbreaks in hospitalised 
patients involve transmission of yeasts via contaminated surfaces and health-care workers’ 
hands. Routine antifungal prophylaxis for some high-risk patient groups and guidelines for 
environmental infection control aim to prevent IFIs among hospitalised patients;46 however, 
outbreaks continue to occur despite these practices. Other health-care-associated IFI 
outbreaks include those caused by medical products or medications contaminated with 
fungal pathogens. Contamination of pharmaceuticals with a wide range of fungal species has 
been increasingly reported over the past decade, and resulting outbreaks are complex and 
often expose pharmaceutical regulatory gaps. Lastly, a small number of IFI outbreaks in 
organ transplant recipients have been associated with receipt of infected donor organs.
In-hospital environment
Outbreaks of hospital-associated invasive mould infections (IMIs) have become increasingly 
prominent, especially among severely immunocompromised patients, including those with 
haematological malignancies, haemopoietic stem cell transplants, and solid organ transplant 
recipients.47–49 Moulds are ubiquitous in the environment, and opportunities for hospital-
associated IMI outbreaks arise when severely immunocompromised patients (eg, patients 
who have just received a bone marrow transplant and are in the pre-engraftment stage or 
patients who are persistently neutropenic due to underlying malignancy or chemotherapy) 
are exposed to building environments with inadequate air filtration, ongoing construction, 
water damage, and air pressure differentials. Although most hospital-associated IMI 
outbreaks are caused by Aspergillus spp,47 mucormycosis outbreaks among hospitalised 
patients in the USA appear to have become more common. The shift from aspergillus to 
mucormycetes as the causative organism in outbreaks might be due to increasing use of 
voriconazole prophylaxis in highly immunocompromised patients; voriconazole is active 
against Aspergillus spp but not mucormycetes. Increases in mould outbreaks could also be a 
result of the increasing number and acuity of patients receiving bone marrow and solid organ 
transplants and intensive chemotherapy. Three IMI outbreaks in hospitals are described 
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below to illustrate the types of problems that can occur in hospitals and lead to such 
outbreaks.
A mucormycosis cluster occurred among four solid organ transplant recipients in 
Pennsylvania between May, 2014, and September, 2015.50 Although the patients did not 
have a clinical indication for negative-pressure isolation, three of the four received care in 
the same negative-pressure isolation room. Negative-pressure rooms draw air from the 
hallway and other parts of the hospital unit into the patient’s room and can increase the 
chance of dust and mould exposure. This investigation led to the important finding that 
hospitals should avoid placing high-risk patients in negative-pressure rooms unless 
indicated.50 In another outbreak, during March–June, 2015, five mucormycosis cases were 
observed among bone marrow transplant recipients at a hospital in Colorado where 
construction was ongoing in an adjacent unit. A definitive source could not be identified, but 
mould that accumulated in the wall due to a slow water leak might have had a role.51 Mould 
caused by water leaks is a recurrent theme in hospital outbreaks. Immediately addressing 
water damage is an important strategy to reduce mould, especially in hospital areas with 
highly immunocompromised patients.
During July–November, 2014, five patients with haematological malignancies developed 
rhinocerebral mucormycosis at a hospital in Kansas.52 The infections, caused by several 
different mucormycetes, coincided with nearby construction, and the patients were placed in 
rooms that shared a hallway with construction traffic.53 Hospital construction is a well 
recognised risk factor for mould infection, and infection control risk assessments are 
recommended before beginning construction or other activities that could generate dust or 
moisture, which might disperse mould spores.46 Although care was taken to implement 
control measures within the construction zone in this outbreak, similar precautions were not 
taken outside the construction zone, with workers using the same hallway as patients on a 
haematology/oncology ward. This outbreak highlights the importance of ensuring complete 
separation of patients and construction activities and personnel, even outside construction 
areas.52
Recent mucormycosis outbreaks highlight the need to pay close attention to the hospital 
environment. Investigating these outbreaks presents several challenges. First, because there 
is no routine surveillance for mould infections, and cases in an outbreak often occur over 
several months, it is difficult to determine if and when an outbreak is occurring. Second, 
numbers of outbreak-associated cases are often small, and case-control studies to determine 
common exposure might not yield any significant results. Last, more research is needed to 
understand the optimal indoor environments in hospitals and how to achieve and maintain 
those standards. In the USA and Europe, no standards exist for airborne mould 
concentrations, and the value of routine hospital air sampling is unclear,53 although a study 
from Spain identified high levels of airborne Aspergillus fumigatus associated with 
aspergillosis cases in patients undergoing heart surgery.54
Similar challenges are evident during investigations of other hospital-associated mould 
infections, such as Bipolaris spp surgical site infections in 21 patients undergoing 
cardiothoracic surgery at ten hospitals in Texas, Arkansas, and Florida, during 2008–13.55 
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Bipolaris surgical site infections had been rarely reported previously, raising suspicion that a 
common source might be responsible for this observed temporal and geographical 
clustering. However, epidemiological investigation did not reveal shared exposures, and the 
genetic diversity among isolates detected by multilocus sequence typing (MLST) was also 
consistent with multiple environmental sources.56 Investigation of another outbreak caused 
by a different pathogen (C neoformans) not known to result in clusters of infection or be 
transmitted in a health-care setting also did not reveal a common source. This unusual 
cluster involved six patients at a community hospital in Arkansas, where four patients 
developed C neoformans bloodstream infection and two developed respiratory infections 
during April–December, 2013. Clinical isolates from the six patients had three separate 
MLST patterns, suggesting either a point source consisting of multiple cryptococcus strains 
or an unknown non-point source.57 The investigation revealed that short-term steroid use 
was associated with increased risk for cryptococcosis, which had not been previously 
described for this infection.57 Thorough investigation of possible outbreaks of hospital-
associated IFIs is needed to better understand their sources and to guide prevention 
measures.
Candida is a common pathogen causing health-care-associated bloodstream infections.58 
However, candidaemia outbreaks are relatively infrequent, probably because many Candida 
species are commensal organisms, and most cases of invasive candidiasis arise from 
patients’ own gastrointestinal or skin flora. Outbreaks with species such as Candida 
parapsilosis and Candida tropicalis do occur, typically among patients in neonatal intensive 
care units, and have been associated with transmission via health-care workers’ hands or 
environmental surfaces.59–61 Outbreaks of Candida auris, a newly emerging, multidrug-
resistant yeast, have occurred in the UK and several other countries; early evidence suggests 
that C auris might be transmitted in health-care settings.62,63
There has been an overall decline in candidaemia in neonatal intensive care unit populations; 
these declines could be due to increased use of antifungal prophylaxis, improvements in 
central venous catheter insertion and maintenance, antibiotic stewardship practices, or under-
recognition or under-reporting of small clusters.64 The observed shift in the distribution of 
species causing invasive candidiasis towards more non-Candida albicans species is 
concerning given the high rates of antifungal resistance in several of these species, 
particularly Candida glabrata.65 Multisite population-based candidaemia surveillance in the 
USA indicates that although fluconazole resistance rates have remained stable or decreased, 
echinocandin resistance rates have increased.64 Furthermore, echinocandin non-susceptible 
C glabrata infections appear to be concentrated in a few hospitals, and more than half of 
these cases occurred in people with no known prior echinocandin exposure, suggesting 
possible environmental or person-to-person transmission mechanisms.66
Contaminated medical products
Since 2000, several IFI outbreaks in the USA have been linked to contaminated 
pharmaceuticals produced by compounding pharmacies.67 Facility inspections revealed 
deficiencies in production practices, including problems with flow hoods, inadequate 
training, absence of environmental sampling, and presence of mould in clean areas. These 
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outbreaks suggest that clinicians and investigators should remain vigilant for IFIs potentially 
linked to contaminated medical products.
One of the most remarkable and largest known health-care-associated IFI outbreaks occurred 
in the USA in 2012–13, and involved 753 cases of Exserohilum rostratum infection. Patients 
who received injections of contaminated preservative-free methylprednisolone from a single 
compounding pharmacy developed meningitis, localised spinal and paraspinal infections, 
and peripheral joint infections.68 Close collaboration between local, state, and federal health 
agencies and clinicians resulted in rapid public health actions, including recall of the 
contaminated methylprednisolone, notification of nearly 14 000 people who were potentially 
exposed to the product, and development and dissemination of diagnostic and treatment 
guidance for this unfamiliar clinical entity.69,70 These public health actions were estimated 
to save more than 100 lives.69 Although no molecular typing methods for E rostratum or 
knowledge of its population structure existed at the time of the outbreak, WGST analysis of 
28 isolates from patients and the contaminated methylprednisolone indicated nearly identical 
genomes.70 No more than two single nucleotide polymorphisms (SNPs) separated any of the 
isolates, whereas substantial genetic diversity (more than 20 000 SNPs) was observed among 
unrelated control isolates.70
Similar fungal contamination of two different compounded products led to an outbreak 
involving 47 cases of fungal endophthalmitis, including 21 cases linked to Brilliant Blue G 
intraocular dye (used during retinal surgery) contaminated with Fusarium incarnatum-
equiseti species complex, and 26 cases linked to intravitreal injection of triamcinolone 
acetate contaminated with Bipolaris hawaiiensis.71 Both products were produced by a single 
compounding pharmacy in Florida, which suspended its sterile compounding services and 
recalled all of its sterile compounded products.71 Genetic similarity among six of the 
bipolaris isolates by MLST indicated that these infections were probably linked to 
contaminated triamcinolone. This finding contrasts with the heterogeneity of bipolaris 
isolates observed in the outbreak among patients undergoing cardiothoracic surgery.56
Contaminated antinausea medication was implicated in an outbreak of Sarocladium kiliense 
bloodstream infections among more than 50 paediatric oncology patients in Colombia and 
Chile during 2013–14.72 WGST done on 25 isolates from patients and the contaminated 
medication confirmed the antinausea medication as the likely outbreak source.72
Donor-derived IFIs in organ-transplant recipients
Cases and small clusters of IFIs transmitted through donation of infected organs are rare but 
can result in serious complications.73 Known donor-derived IFIs include histoplasmosis, 
coccidioidomycosis, cryptococcosis, and various mould infections. Microsporidiosis also 
appears to be an emerging donor-derived IFI; in the first known donor-derived cluster of this 
infection, three transplant recipients developed Encephalitozoon cuniculi infection after 
receiving organs from the same donor.74 Recognition of IFIs transmitted through infected 
organs remains challenging, since distinguishing these infections from IFI acquired post-
transplantation or reactivation of latent IFI can be difficult. Further efforts to improve 
recognition of these infections, including determining the importance of donor screening 
practices, are needed.
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Conclusions
IFI outbreaks are highly diverse, are caused by many different fungal pathogens, affect a 
wide variety of populations and settings, and are linked to numerous sources. Outbreak-
associated IFI cases represent a small proportion of all IFIs, but these cases frequently 
provide new and important epidemiological information and a better understanding of the 
environmental niches of the causative fungi. Furthermore, outbreaks often reveal emerging 
areas of concern that apply to IFIs in general. These topics include IFIs in new populations 
at risk due to factors such as travel or relocation, occupation, or immunosuppression;37,39,57 
IFIs associated with unusual events and sources such as natural disasters43,45 and 
contaminated medications, often with unexpected pathogens;68,71,72 and fungal pathogens 
appearing in geographic regions in which they have not been previously recognised.22,31
In addition to these emerging issues, IFI outbreaks highlight long-standing clinical and 
public health challenges. These challenges include the need for more rapid and accurate 
diagnostic tools for many IFIs and additional methods to determine immunity, which is 
especially important for endemic mycoses. Other questions pertinent to endemic mycoses 
include the utility and feasibility of personal protective equipment and environmental 
remediation methods. In community-acquired and health-care-associated IFI outbreaks, an 
environmental point source is not always apparent,42,55 and interpreting environmental 
sampling (figure 2) results can be challenging, particularly in health-care settings. Health-
care infection control, especially as it relates to hand hygiene, construction, and management 
of indoor air quality and environment, continues to be important in IFI outbreaks. Antifungal 
stewardship practices also deserve continued attention, particularly given the increases in 
resistant fungal pathogens and the sometimes very expensive and toxic nature of some 
antifungal therapies. Last, because primary prevention is challenging for many IFIs, 
particularly those that are community-acquired, increasing awareness of IFIs among health-
care providers and the public remains one of the most important areas for ongoing work in 
this field. Non-specific signs and symptoms can make IFIs difficult to identify, and improved 
methodologies are needed for faster and more accurate diagnosis. Advancements in 
molecular methods to diagnose IFIs and molecular typing methods to assess genetic 
relatedness will continue to enhance outbreak investigations.
Health-care provider awareness of IFIs is essential for prompt public health responses to 
outbreaks. In the USA, comprehensive surveillance systems do not exist for most IFIs. 
Routine surveillance would allow for easier detection of increased numbers of cases over 
what could usually be expected during a certain timeframe in a specific area. Clinicians 
should be aware, however, that even two cases of the same type of IFI clustered in time and 
place can raise suspicion for an outbreak. Given changes afoot in the ranges of the 
dimorphic fungi, clinicians who practice outside of these historically defined ranges should 
maintain vigilance for these infections. In most situations, IFI outbreak detection depends on 
astute clinicians recognising the presence of a possible outbreak and communicating the 
problem to local public health authorities.
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Key messages
• Invasive fungal infection (IFI) outbreaks are caused by many different 
pathogens and occur both in the community and health-care settings
• Emerging features of IFI outbreaks include new populations at risk, pathogens 
in geographical areas where they have not previously been recognised, and 
contaminated compounded medications
• Challenges with IFI outbreak recognition, response, and prevention include 
the need for improved rapid diagnostic methods, lack of routine IFI 
surveillance, adherence to health-care infection control practices, and health-
care provider and public awareness
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Search strategy and selection criteria
We searched the US Centers for Disease Control and Prevention Mycotic Diseases 
Branch archives between May, 2016 and June, 2016 for publications and conference 
abstracts describing fungal disease outbreaks from the past decade. We also searched 
PubMed using combinations of the terms “fungal disease”, “mold infection”, “outbreak”, 
“cluster”, and specific fungal diseases (eg, aspergillosis, mucormycosis, 
coccidioidomycosis) with no date or language restrictions. Articles were included if they 
highlighted emerging fungal disease outbreak features or issues, with an emphasis on 
outbreaks in the USA in the past decade.
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Figure 1. Soft-tissue mucormycosis caused by Apophysomyces trapeziformis
Left flank wound in a mucormycosis patient, with macroscopic fungal growth (tissue with 
white, fluffy appearance) and necrotic borders before repeated surgical debridement.43,45
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Figure 2. 
Environmental sampling for Coccicioides spp
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